BofA lowered the firm’s price target on Avidity Biosciences (RNA) to $48 from $51 and keeps a Buy rating on the shares. The firm rolled the quarter, updated for Q4 results, cash and share count, and adjusted operating expense estimates based on management commentary.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Avidity Biosciences initiated with an Outperform at Scotiabank
- Avidity Biosciences: Positioned for Transformative Growth with Promising Pipeline and Strategic Launch Preparations
- Avidity Biosciences Advances RNA Therapeutics for Rare Diseases
- Positive Outlook for Avidity Biosciences Driven by Promising Pipeline Developments and Strong Financial Position